Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV Patients
Author Information
Author(s): Murdoch David M, Venter Willem DF, Van Rie Annelies, Feldman Charles
Primary Institution: Duke University Medical Center
Hypothesis
What are the common infectious manifestations and treatment options for IRIS in HIV-infected patients initiating antiretroviral therapy?
Conclusion
IRIS is a significant problem in HIV patients starting antiretroviral therapy, characterized by clinical deterioration due to immune restoration.
Supporting Evidence
- IRIS can cause a paradoxical worsening of known conditions after starting HIV treatment.
- Common pathogens involved in IRIS include mycobacteria and herpesviruses.
- Treatment for IRIS varies based on the underlying infectious agent.
Takeaway
When people with HIV start treatment, their immune system can get confused and sometimes make them feel worse instead of better. This is called IRIS.
Methodology
The review summarizes existing literature on the pathogenesis, epidemiology, and treatment options for IRIS.
Potential Biases
The studies reviewed may be biased due to their retrospective nature and reliance on clinical suspicion for diagnosis.
Limitations
The overall incidence of IRIS is unknown, and most evidence comes from case reports and small series, lacking robust clinical trials.
Participant Demographics
The review discusses various demographics but does not provide specific participant details.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website